TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06044350
Drug: BAT4406F Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion; Dosage:500mg/time
Study: NCT06044350
Drug: BAT4406F Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion; Dosage:500mg/time
Study: NCT06618079
Drug: HUC2-565-B, HUC2-565-A and HUC2-565-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.
Study: NCT05464381
Drug: allo-APZ2-OTS
Normalized name: allo-2-hydroxycitric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
Study: NCT05464381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05161208
Drug: Placebo (vehicle) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
Study: NCT06058130
Drug: Anticoagulant Oral
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation alone
Study: NCT05734690
Drug: SGLT2i, beta blocker, ARNI, MRA, MTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.
Study: NCT06038058
Drug: BRY812 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRY812 for injection will be administered by intravenous drip, tentatively once per cycle spanning 3 weeks on D1 of each cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
Study: NCT06554847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT06554847
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT04398485
Drug: ION251
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION251 administered by IV infusion
Study: NCT06483048
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06621173
Drug: HNF4α srRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNF4α srRNA will be administered intravenously for the treatment of metastatic colorectal cancer. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
Study: NCT04183738
Drug: NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.
Study: NCT06395610
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeated doses of oral Erythromycin
Study: NCT05678270
Drug: ICP-192
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-192 is a round, uncoated tablet, 5mg, orally.
Study: NCT05678244
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen will be added to standard of care opioid based pain regimes.
Study: NCT05678244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In control group placebo will be added to standard of care opioid based pain regimes.
Study: NCT05299944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT05118776
Drug: ASC40 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC40 tablets administered orally once daily
Study: NCT06225856
Drug: YY201
Normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'YY201'. Drug abbreviations can vary and may not be standardized, so without more context about the specific drug or clinical trial, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration under fasting state.
Study: NCT05118776
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally once daily.
Study: NCT04591990
Drug: Administration of placebo AVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo AVP
Study: NCT04591990
Drug: Administration of placebo hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo hydrocortisone
Study: NCT04591990
Drug: Administration of hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of hydrocortisone
Study: NCT05481528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of placebo
Study: NCT05087914
Drug: Carbidopa-Levodopa (100mg/25mg):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Study: NCT05087914
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Study: NCT05603195
Drug: REGN7508 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered sequential, ascending single intravenous (IV) dose
Study: NCT05603195
Drug: Matching Placebo (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered sequential, ascending single intravenous (IV) dose
Study: NCT05603195
Drug: Matching Placebo (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered sequential, ascending single subcutaneous (SC) dose
Study: NCT05985200
Drug: Placebo matching BI 3032950
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 3032950
Study: NCT00002090
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04988022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04982692
Drug: intravaginal prasterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Study: NCT04982692
Drug: Placebo ovules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Study: NCT05024097
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
Study: NCT06653465
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, which has similarly effects with NSAIDs in terms of inhibition of cyclooxygenase COX1, COX2 and COX3, is widely used as adjuvant for perioperative multimodal analgesia.
Study: NCT06648265
Drug: Tumescent solution with dilute lidocaine and epinephrine
Normalized name: epinephrine / lidocaine Injectable Solution [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm infiltration with traditional Klein\&#39;s tumescent solution
Study: NCT00673751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05325281
Drug: CPI-613® (Dose level -1.0 250 mg/m^2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
Study: NCT06579053
Drug: Spironolactone Tablets (Test)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take one test tablet each period
Study: NCT05325281
Drug: CPI-613® (Dose level 1.0 500 mg/m^2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
Study: NCT05325281
Drug: CPI-613® (Dose level 2.0 1,000 mg/m^2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
Study: NCT06579053
Drug: Spironolactone Tablets (Reference)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take one reference tablet each period
Study: NCT05325281
Drug: CPI-613® Maximum Tolerated Dose (MTD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
Study: NCT06004856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily (QD)
Study: NCT06015503
Drug: PLB1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB1004 is a capsule in the form of 80mg and 40mg.
Study: NCT06659705
Drug: 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.
Study: NCT05354843
Drug: ET0038
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET0038 for oral administration
Study: NCT05352672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06665100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Saline for Inhalation
Study: NCT06032052
Drug: Single drug chemotherapy plus immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
Study: NCT05581303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given by subcutaneous injection once every 12 weeks (Q12W).
Study: NCT05413369
Drug: IDegAsp
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution, by subcutaneous injection
Study: NCT06016010
Drug: USL Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: USL Placebo
Study: NCT06699966
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
Study: NCT06699966
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
Study: NCT04604275
Drug: Sucrase
Normalized name: Sucrase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
Study: NCT06683651
Drug: STN1013800 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product: 0.1% STN1013800 ophthalmic solution
Study: NCT06683651
Drug: STN1013800 ophthalmic solution Liquid Base, without STN1013800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control: STN1013800 ophthalmic solution Liquid Base, without STN1013800
Study: NCT06699407
Drug: Qishenyiqi dripping pills
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Study: NCT06699407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 bag once, three times a day, 12 months
Study: NCT05885035
Drug: Calcium Hydroxyapatite
Normalized name: Calcium hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
Study: NCT05300802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
Study: NCT06144424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once Daily
Study: NCT06698861
Drug: PEG-MetHuG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2
Study: NCT06554509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06152497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT05556200
Drug: VEGFR2 Tyrosine Kinase Inhibitor
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apatinib 250 mg, po, qd
Study: NCT04021121
Drug: Standard dose RIF
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF 10 mg/kg/day
Study: NCT06219824
Drug: premixed Bio-ceramic MTA
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: pulpotomy treatment will be done and the premixed bioceramic MTA will be applied in the pulp chamber
Study: NCT06219824
Drug: Conventional MTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pulpotomy treatment will be done and powder and liquid MTA will be mixed and applied in the pulp chamber
Study: NCT06520982
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused intra-arterially in a dose-response fashion
Study: NCT06520982
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused intra-arterially in a dose-response fashion
Study: NCT05507476
Drug: Epinephrine topical 1:100,000 Nasal Packs
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
Study: NCT05655286
Drug: 38% SDF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with active caries will receive 38% silver diamine fluoride treatment
Study: NCT04654988
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine: 2 mg/kg daily for 12 months
Study: NCT04654988
Drug: Placebo Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo Azathioprine
Study: NCT05814809
Drug: JP-1366 20mg tablet
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: T : JP-1366 20mg tablet
Study: NCT05814809
Drug: JP-1366 20mg capsule
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: R : JP-1366 20mg capsule
Study: NCT05296044
Drug: JT-003 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT05793450
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0mg, SC, single dose
Study: NCT06489327
Drug: melatonin (Circadin ®) 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral melatonin at a dose of 0.2 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Study: NCT06489327
Drug: melatonin (Circadin ®) 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral melatonin at a dose of 0.4 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Study: NCT06489327
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral placebo as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Study: NCT05836740
Drug: Minocycline hydrochloride capsule
Normalized name: Minocycline Hydrochloride Capsules
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg per capsule, containing 50mg of Minocycline Hydrochloride.
Study: NCT05836740
Drug: Placebo capsules of Minocycline hydrochloride capsules
Normalized name: minocycline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg per capsule, containing 0mg of Minocycline Hydrochloride.
Study: NCT05347238
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
Study: NCT05347238
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
Study: NCT05115344
Drug: flonoltinib 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study: NCT05115344
Drug: flonoltinib 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study: NCT05115344
Drug: flonoltinib 225mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study: NCT05115344
Drug: flonoltinib 325mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Study: NCT06620393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 100ml
Study: NCT04707703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
Study: NCT00095641
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06074809
Drug: Modified Guizhi Fuling granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
Study: NCT04181515
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo stressor
Study: NCT04181515
Drug: Yohimbine + Hydrocortisone
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 54mg + Hydrocortisone 20mg
Study: NCT04803734
Drug: Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI, 2 puffs, single dose, fasting
Study: NCT05700916
Drug: Milk Polar Lipid-Rich Dairy Powder
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
Study: NCT06008197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo
Study: NCT01641796
Drug: Paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin Topical Cream applied to all lesions once a day for 20 days
Study: NCT06618820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose consists of three microcrystalline cellulose capsules.
Study: NCT05959096
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05067439
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 100 mg
Study: NCT06472531
Drug: INR101
Approvals — FDA: no, EMA: no, PMDA: no
Description: • 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
Study: NCT06472531
Drug: INR101
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT~* 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
Study: NCT06293989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups:Placebo . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
Study: NCT04871061
Drug: Conventional opioid analgesia (Fentanyl)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: standardised intravenous opioid
Study: NCT06410703
Drug: CAN1012
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W